The potential and hurdles of targeted alpha therapy - clinical trials and beyond

Frontiers in Oncology

Volumn 4 JAN, Issue , 2014, Pages

  Elgqvist, Jörgen ^a,b,c   Frost, Sofia ^d   Pouget, Jean Pierre ^a,b,c   Albertsson, Per ^e  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b UNIV MONTPELLIER   (France)

^c CENTRE VAL D AURELLE   (France)

^d USA   (United States)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alpha emitters; Cancer; Dosimetry; Ovarian cancer; Radionuclide therapy; Targeted alpha therapy

Indexed keywords

ACTINIUM 225; ASTATINE 211; BISMUTH 212; BISMUTH 213; LEAD 212; LUTETIUM 177; MONOCLONAL ANTIBODY; RADIOISOTOPE; RADIUM CHLORIDE RA 223; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ALPHA RADIATION; CANCER PALLIATIVE THERAPY; DOSIMETRY; DRUG DOSE ESCALATION; GLIOBLASTOMA; HUMAN; INTESTINE EPITHELIUM; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RADIATION DOSE; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCANNING ELECTRON MICROSCOPY;

EID: 84893690105     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00324     Document Type: Review

References (89)

1. Olafsen T, Elgqvist J, Wu AM. Protein targeting constructs in alpha therapy. Curr Radiopharm (2011) 4(3):197-213. doi:10.2174/1874471011104030197
2. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy (2011) 3(3):349-70. doi:10.2217/imt.10.114
3. Dong C, Liu Z, Wang F. Peptide-based radiopharmaceuticals for targeted tumor therapy. Curr Med Chem (2013) 21(1):139-52.
4. Pool SE, Krenning EP, Koning GA, van Eijck CH, Teunissen JJ, Kam B, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med (2010) 40(3):209-18. doi:10.1053/j.semnuclmed.2009.12.001
5. Muller C, Schibli R. Prospects in folate receptor-targeted radionuclide therapy. Front Oncol (2013) 3:249. doi:10.3389/fonc.2013.00249
6. Olafsen T, Kenanova VE, Wu AM. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc (2006) 1(4):2048-60. doi:10.1038/nprot.2006.322
7. Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8, Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging (2010) 37(7):1335-44. doi:10.1007/s00259-010-1385-5
8. Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, Hofer S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res (2006) 12(12):3843-50. doi:10.1158/1078-0432.CCR-05-2820
9. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med (2008) 49(1):30-8. doi:10.2967/jnumed.107.046938
10. Andersson H, Cederkrantz E, Back T, Divgi C, Elgqvist J, Himmelman J, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2-a phase I study. J Nucl Med (2009) 50(7):1153-60. doi:10.2967/jnumed.109.062604
11. Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, et al. Pharmacokinetics and imaging of (212)Pb-TCMC-Trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm (2014) 29(1):12-7. doi:10.1089/cbr.2013.1531
12. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 100(4):1233-9.
13. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res (2010) 16(21):5303-11. doi:10.1158/1078-0432.ccr-10-0382
14. Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 40(11):1935-46.
15. Memorial Sloan Kettering Cancer C, National Cancer Institute, Actinium Pharmaceuticals. Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies. U.S. National Institutes of Health (2014).
16. M.D. Anderson Cancer Center, Actinium Pharmaceuticals. Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients. U.S. National Institutes of Health (2015).
17. Heeger S, Moldenhauer G, Egerer G, Wesch H, Martin S, Nikula T, et al., editors. Alpha radioimmunotherapy of B-lineage non-Hodgkin's lymphoma using 213Bi-labeled anti-CD19-and anti-CD20-CHX-A"-DTPA conjugates. Proceedings of the 225th ACS National Meeting, Division of Nuclear Chemistry & Technology; 2003 March 23-27; New Orleans, LA, USA. (2003). Available from: http://oasys2.confex.com/acs/225nm/techprogram/P613172.HTM
18. Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Graham P, et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther (2005) 4(12):1318-24. doi:10.4161/cbt.4.12.2251
19. Allen BJ, Singla AA, Rizvi SM, Graham P, Bruchertseifer F, Apostolidis C, et al. Analysis of patient survival in a phase I trial of systemic targeted alpha-therapy for metastatic melanoma. Immunotherapy (2011) 3(9):1041-50. doi:10.2217/imt.11.97
20. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 369(3):213-23. doi:10.1056/NEJMoa1213755
21. Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, Starkhammar H, et al. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol (2005) 44(8):904-12. doi:10.1080/02841860500355900
22. Palm S, Elgqvist J, Jacobsson L. Patient-specific alpha-particle dosimetry. Curr Radiopharm (2011) 4(4):329-35. doi:10.2174/1874471011104040329
23. Vaidyanathan G, Boskovitz A, Shankar S, Zalutsky MR. Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers. Peptides (2004) 25(12):2087-97. doi:10.1016/j.peptides.2004.08.018
24. Senekowitsch-Schmidtke R, Schuhmacher C, Becker KF, Nikula TK, Seidl C, Becker I, et al. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res (2001) 61(7):2804-8.
25. Bayer. Re-Treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases. U.S. National Institutes of Health (2017).
26. Algeta ASA, Bayer. A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC). U.S. National Institutes of Health (2014).
27. M.D. Anderson Cancer Center, Bayer. Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma. U.S. National Institutes of Health (2016).
28. Bodet-Milin C, Ferrer L, Pallardy A, Eugene T, Rauscher A, Alain F-C, et al. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Front Oncol (2013) 3:177. doi:10.3389/fonc.2013.00177
29. Morgenstern A, Lebeda O, Stursa J, Bruchertseifer F, Capote R, McGinley J, et al. Production of 230U/226Th for targeted alpha therapy via proton irradiation of 231Pa. Anal Chem (2008) 80(22):8763-70. doi:10.1021/ac801304c
30. Bäck T, Chouin N, Lindegren S, Jensen H, Palm S, Albertsson P. Tumor growth of subcutaneous xenografts after repeated alpha-radioimmunotherapy with astatine-211: what absorbed dose is required to treat solid tumors with alpha emitters? Eur J Nucl Med Mol Imaging (2012) 39(Suppl 2):S324.
31. Morgan RJ Jr, Alvarez RD, Armstrong DK, Chen LM, Copeland L, Fowler J, et al. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 4(9):912-39.
32. Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in ovarian cancer. Acta Oncol (2003) 42(5-6):562-6. doi:10.1080/02841860310014426
33. Rosenshein NB, Leichner PK, Vogelsang G. Radiocolloids in the treatment of ovarian cancer. Obstet Gynecol Surv (1979) 34(9):708-20.
34. Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, et al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol (2003) 21(15):2849-55. doi:10.1200/JCO.2003.11.018
35. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 354(1):34-43. doi:10.1056/NEJMoa052985
36. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev (2011) 9(11):CD005340. doi:10.1002/14651858.CD005340.pub3
37. Andersson H, Elgqvist J, Horvath G, Hultborn R, Jacobsson L, Jensen H, et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res (2003) 9(10 Pt 2):3914S-21S.
38. Ward BG, Mather SJ, Hawkins LR, Crowther ME, Shepherd JH, Granowska M, et al. Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration. Cancer Res (1987) 47(17):4719-23.
39. Oei AL, Verheijen RH, Seiden MV, Benigno BB, Lopes A, Soper JT, et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer (2007) 120(12):2710-4. doi:10.1002/ijc.22663
40. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol (2006) 24(4):571-8. doi:10.1200/jco.2005.02.5973
41. Palm S, Humm JL, Rundqvist R, Jacobsson L. Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys (2004) 31(2):218-25. doi:10.1118/1.1640951
42. Apostolidis C, Molinet R, McGinley J, Abbas K, Mollenbeck J, Morgenstern A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot (2005) 62(3):383-7. doi:10.1016/j.apradiso.2004.06.013
43. Zalutsky MR, Pruszynski M. Astatine-211: production and availability. Curr Radiopharm (2011) 4(3):177-85. doi:10.2174/1874471011104030177
44. International Commission on Radiological Protection. Committee 4. Report of Committee IV on Evaluation of Radiation Doses to Body Tissues from International Contamination Due to Occupational Exposure. 1st ed. Oxford: Pergamon (1968). 94 p.
45. Loevinger R, Berman M. A formalism for calculation of absorbed dose from radionuclides. Phys Med Biol (1968) 13(2):205-17. doi:10.1088/0031-9155/13/2/306
46. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry - standardization of nomenclature. J Nucl Med (2009) 50(3):477-84. doi:10.2967/jnumed.108.056036
47. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med (2010) 51(2):311-28. doi:10.2967/jnumed.108.058651
48. Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res (2006) 12(20 Pt 2):6250s-7s. doi:10.1158/1078-0432.CCR-06-0841
49. Sjogreen K, Ljungberg M, Strand SE. An activity quantification method based on registration of CT and whole-body scintillation camera images, with application to 131I. J Nucl Med (2002) 43(7):972-82.
50. Chouin N, Bardies M. Alpha-particle microdosimetry. Curr Radiopharm (2011) 4(3):266-80. doi:10.2174/1874471011104030266
51. Rossi HH, Rosenzweig W. A device for the measurement of dose as a function of specific ionization. Radiology (1955) 64(3):404-11. doi:10.1148/64.3.404
52. Kassis AI, Harris CR, Adelstein SJ, Ruth TJ, Lambrecht R, Wolf AP. The in vitro radiobiology of astatine-211 decay. Radiat Res (1986) 105(1):27-36. doi:10.2307/3576722
53. Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus. Radiat Res (1991) 128(2):204-9. doi:10.2307/3578139
54. Walicka MA, Vaidyanathan G, Zalutsky MR, Adelstein SJ, Kassis AI. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat Res (1998) 150(3):263-8. doi:10.2307/3579974
55. Barendsen GW. Impairment of the proliferative capacity of human cells in culture by alpha-particles with differing linear-energy transfer. Int J Radiat Biol Relat Stud Phys Chem Med (1964) 8:453-66. doi:10.1080/09553006414550561
56. Barendsen GW, Beusker TL. Effects of different ionizing radiations on human cells in tissue culture. I. Irradiation techniques and dosimetry. Radiat Res (1960) 13:832-40. doi:10.2307/3570858
57. Barendsen GW, Beusker TL, Vergroesen AJ, Budke L. Effects of different radiations on human cells in tissue culture. II. Biological experiments. Radiat Res (1960) 13:841-9. doi:10.2307/3570859
58. Barendsen GW, Walter HM. Effects of different ionizing radiations on human cells in tissue culture. IV. Modification of radiation damage. Radiat Res (1964) 21:314-29. doi:10.2307/3571569
59. Barendsen GW, Walter HM, Fowler JF, Bewley DK. Effects of different ionizing radiations on human cells in tissue culture. III. Experiments with cyclotron-accelerated alpha-particles and deuterons. Radiat Res (1963) 18:106-19. doi:10.2307/3571430
60. Raju MR, Eisen Y, Carpenter S, Jarrett K, Harvey WF. Radiobiology of alpha particles. IV. Cell inactivation by alpha particles of energies 0.4-3.5 MeV. Radiat Res (1993) 133(3):289-96. doi:10.2307/3578212
61. Eccles LJ, O'Neill P, Lomax ME. Delayed repair of radiation induced clustered DNA damage: friend or foe? Mutat Res (2011) 711(1-2):134-41. doi:10.1016/j.mrfmmm.2010.11.003
62. Gulston M, de Lara C, Jenner T, Davis E, O'Neill P. Processing of clustered DNA damage generates additional double-strand breaks in mammalian cells post-irradiation. Nucleic Acids Res (2004) 32(4):1602-9. doi:10.1093/nar/gkh306
63. Pouget JP, Navarro-Teulon I, Bardies M, Chouin N, Cartron G, Pelegrin A, et al. Clinical radioimmunotherapy - the role of radiobiology. Nat Rev Clin Oncol (2011) 8(12):720-34. doi:10.1038/nrclinonc.2011.160
64. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys (1990) 18(5):1261-9. doi:10.1016/0360-3016(90)90467-X
65. Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys (2004) 59(5):1274-87. doi:10.1016/j.ijrobp.2004.02.065
66. Paillas S, Boudousq V, Piron B, Kersual N, Bardies M, Chouin N, et al. Apoptosis and p53 are not involved in the anti-tumor efficacy of (1)(2)(5)I-labeled monoclonal antibodies targeting the cell membrane. Nucl Med Biol (2013) 40(4):471-80. doi:10.1016/j.nucmedbio.2013.02.001
67. Williams JA, Edwards JA, Dillehay LE. Quantitative comparison of radiolabeled antibody therapy and external beam radiotherapy in the treatment of human glioma xenografts. Int J Radiat Oncol Biol Phys (1992) 24(1):111-7. doi:10.1016/0360-3016(92)91029-M
68. Alper T. Lethal mutations and cell death. Phys Med Biol (1963) 66:365-85. doi:10.1088/0031-9155/8/4/301
69. Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med (1994) 180(2):525-35. doi:10.1084/jem.180.2.525
70. Hanot M, Hoarau J, Carriere M, Angulo JF, Khodja H. Membrane-dependent bystander effect contributes to amplification of the response to alpha-particle irradiation in targeted and nontargeted cells. Int J Radiat Oncol Biol Phys (2009) 75(4):1247-53. doi:10.1016/j.ijrobp.2009.07.014
71. Jain MR, Li M, Chen W, Liu T, de Toledo SM, Pandey BN, et al. In vivo space radiation-induced non-targeted responses: late effects on molecular signaling in mitochondria. Curr Mol Pharmacol (2011) 4(2):106-14. doi:10.2174/1874467211104020106
72. Pouget JP, Santoro L, Raymond L, Chouin N, Bardies M, Bascoul-Mollevi C, et al. Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res (2008) 170(2):192-200. doi:10.1667/RR1359.1
73. Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther (2007) 6(3):789-801. doi:10.1158/1535-7163.MCT-06-0596
74. Yang G, Wu L, Chen S, Zhu L, Huang P, Tong L, et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs radiation-induced bystander effect. Br J Cancer (2009) 100(12):1912-6. doi:10.1038/sj.bjc.6605087
75. Demaria S, Formenti SC. Radiotherapy effects on anti-tumor immunity: implications for cancer treatment. Front Oncol (2013) 3:128. doi:10.3389/fonc.2013.00128
76. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 105(4):256-65. doi:10.1093/jnci/djs629
77. Lorimore SA, Rastogi S, Mukherjee D, Coates PJ, Wright EG. The influence of p53 functions on radiation-induced inflammatory bystander-type signaling in murine bone marrow. Radiat Res (2013) 179(4):406-15. doi:10.1667/RR3158.2
78. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med (2003) 44(3):400-11.
79. Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging (2006) 50(4):248-64.
80. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med (1988) 29(2):226-34.
81. Lesch HP, Kaikkonen MU, Pikkarainen JT, Yla-Herttuala S. Avidin-biotin technology in targeted therapy. Expert Opin Drug Deliv (2010) 7(5):551-64. doi:10.1517/17425241003677749
82. Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther (2002) 1(7):553-63.
83. Pagel JM, Kenoyer AL, Back T, Hamlin DK, Wilbur DS, Fisher DR, et al. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood (2011) 118(3):703-11. doi:10.1182/blood-2011-04-347039
84. Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood (2010) 116(20):4231-9. doi:10.1182/blood-2010-05-282327
85. Zhang M, Zhang Z, Garmestani K, Schultz J, Axworthy DB, Goldman CK, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA (2003) 100(4):1891-5. doi:10.1073/pnas.0437788100
86. Frost SH, Back T, Chouin N, Hultborn R, Jacobsson L, Elgqvist J, et al. Comparison of (211)At-PRIT and (211)At-RIT of ovarian microtumors in a nude mouse model. Cancer Biother Radiopharm (2013) 28(2):108-14. doi:10.1089/cbr.2012.1281
87. Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, Jensen H, et al. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. Nucl Med Biol (2006) 33(8):1065-72. doi:10.1016/j.nucmedbio.2006.07.009
88. Jackson MR, Falzone N, Vallis KA. Advances in anticancer radiopharmaceuticals. Clin Oncol (2013) 25(10):604-9. doi:10.1016/j.clon.2013.06.004
89. Das T, Pillai MR. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol (2013) 40(1):23-32. doi:10.1016/j.nucmedbio.2012.09.007